Science Resources
Earth Science
Space Science
Life Science
Fields of Scientific Study
Medical Topics and Fields
Cancer Research
Nanotechnology Articles
RSS Feeds
|
 |
 |
 |
NIST membrane model may unlock secrets of early-stage Alzheimer's
July 24, 2008
Researchers at the National Institute of Standards and Technology (NIST) and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer's disease actually impairs a neuron's structure and function. The team's findings are reported in a new paper in the Biophysical Journal.* The brain's neurons transmit nerve impulses down a long stem that is surrounded by a two-layer membrane. In the neuron's normal, "rest" state, this membrane actively sorts sodium ions to the outside of the cell and potassium ions to the inside. To transmit a nerve impulse, an electrochemical change ripples down the membrane in advance of the impulse, making it temporarily more permeable and allowing the ions to swap places. That in turn changes the electrical potential across the membrane, allowing the impulse to pass. Afterwards, the membrane returns to rest and begins sorting the ions again.
Medical experts have hypothesized for years that small polypeptides called amyloid beta peptides somehow create a "leaky" membrane that disrupts this balanced back-and-forth switching of the electrical potential and, in turn, normal impulse transmission. Alzheimer's disease-the progressive brain disorder that is the nation's sixth leading cause of death-is believed to start with such breakdowns. As the disease progresses, amyloid beta peptides clump together to form plaques that further destroy nerve function.
Studying the beginnings of Alzheimer's is nearly impossible in humans because by the time the disease is diagnosed, most patients have moved into its later stages. Researchers at NIST have developed a laboratory model that recreates a simplified version of the nerve cell membrane, allowing the study of Alzheimer's disease mechanisms at the molecular level. A clever piece of molecular-level design, the system is built by first covering a silica surface with gold. Sulfur atoms, which bond well to gold, are then added to act as anchors to hold the bilayer membrane. The result is a stable, tethered membrane with an aqueous environment on both sides that accurately models the behavior of the nerve cell membrane.
A collaborative team of researchers from NIST, Carnegie Mellon University, the University of California-Irvine and the Biochemistry Institute (BCHI) in Vilnius, Lithuania, exposed the membrane model to different concentrations of a specific form of amyloid beta peptides comprised of soluble, tiny (5-6 nanometers, approximately twice the diameter of a DNA helix) chains. The researchers found increased cation movement across the normally strong barrier at the higher concentrations of the peptides. The data support the hypothesis that membrane "leakiness" is not due to a permanent hole being formed but rather to an aggregation of amyloid beta peptides in the membrane that allows cations to be passed from peptide to peptide across the bilayer, like a baton handed off by relay runners.
The researchers are continuing to use their model system to better understand the role amyloid beta peptides play in early-stage Alzheimer's disease. Future plans include investigating how amyloid beta peptide aggregates arrange themselves in the membrane, how the peptide aggregates affect or influence calcium channels (portals for calcium ion movement) in the membrane, and how the peptides interact with membranes constructed with other types of lipids.
National Institute of Standards and Technology (NIST)
|
 |
Related Amyloid Beta Current Events and Amyloid Beta News Articles Amyloid Beta Current Events and Amyloid Beta News RSS Novel mouse gene reduces major pathologies associated with Alzheimer's disease A new study reveals that a previously undiscovered mouse gene reduces the two major pathological perturbations commonly associated with Alzheimer's disease (AD).
Mouse gene suppresses Alzheimer's plaques and tangles Investigators at Burnham Institute for Medical Research (Burnham) and colleagues have identified a novel mouse gene (Rps23r1) that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau.
Amyloid beta protein gets bum rap While too much amyloid beta protein in the brain is linked to the development of Alzheimer's disease, not enough of the protein in healthy brains can cause learning problems and forgetfulness, Saint Louis University scientists have found.
Hybrid molecules show promise for exploring, treating Alzheimer's One of the many mysteries of Alzheimer's disease is how protein-like snippets called amyloid-beta peptides, which clump together to form plaques in the brain, may cause cell death, leading to the disease's devastating symptoms of memory loss and other mental difficulties.
Manipulating Brain Inflammation May Help Clear Brain of Amyloid Plaques, Mayo Clinic Researchers Say In a surprising reversal of long-standing scientific belief, researchers at the Mayo Clinic campus in Florida have discovered that inflammation in the brain is not the trigger that leads to buildup of amyloid deposits and development of Alzheimer's disease.
Enzyme may be a key to Alzheimer's-related cell death A Purdue University researcher has discovered that the amount of an enzyme present in neurons can affect the mechanism thought to cause cell death in Alzheimer's disease patients and may have applications for other diseases such as stroke and heart attack.
Rethinking Alzheimer's disease and its treatment targets The standard explanation for what causes Alzheimer's is known as the amyloid hypothesis, which posits that the disease results from of an accumulation of the peptide amyloid beta, the toxic protein fragments that deposit in the brain and become the sticky plaques that have defined Alzheimer's for more than 100 years.
Ben-Gurion University Alzheimer's researcher demonstrates specific immune response to vaccine A researcher who is working on a vaccine for Alzheimer's disease (AD) has demonstrated that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients.
Scientists begin to untangle root cause of Alzheimer's disease "N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change.
Blood flow in Alzheimer's disease Researchers have discovered that the enzyme, endothelin converting enzyme-2 (ECE-2), may cause the decrease in blood flow in the brain seen in Alzheimer's disease and contribute to progression of the disease. More Amyloid Beta Current Events and Amyloid Beta News Articles
|
 |

|
The Nature and Origin of Amyloid Fibrils (Novartis Foundation Symposia)
by CIBA Foundation Symposium (Author)
The term amyloid fibril refers to a protein that has self-assembled into an insoluble antiparallel β-pleated sheet quaternary structure. This process is known as amyloidogenesis, and in combination with other non-protein components these fibrils give rise to the amyloid plaques that are seen in a number of pathological processes. As recently as 25 years ago, amyloid fibrils were thought to represent a single protein entity on the basis of their unique morphological and protein-organizational characteristics. Subsequently it has been shown that a number of different amyloid proteins existso far almost 20 have been identified, each associated with a particular disorder. Among these, β-amyloid forms plaques in the brains of individuals with Alzheimers disease and Downs syndrome,...
|
![[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg)](http://ecx.images-amazon.com/images/I/31Y1NF0J0EL._SL160_.gif)
|
[beta]-amyloid Peptide (1-42), Human, Oncogene - Size 250 Ug - Model Pp69--25mg - Each (.25 Mg)
by Oncogene
[beta]-Amyloid Peptide (1-42), Human, Oncogene - Size 250 ug - Model PP69--25MG - Each (.25 MG) : Lyophilized.Synthetic peptide corresponding to amino acids 1-42 of the processed human amyloid peptide. Supplied in a form that is not neurotoxic prior to preincubation. The level of toxicity has recently been shown to correlate to the extent of beta sheet structure. Reconstitute with degassed HPLC grade deionized water. Purity: >95% by HPLC. FW: 4 kDa.
|

|
Fibrous Proteins: Amyloids, Prions and Beta Proteins, Volume 73 (Advances in Protein Chemistry)
by John M. Squire (Author), David A.D. Parry (Author), Andrey Kajava (Author)
Amyloids, Prions and Beta Proteins is the last volume of the three-part thematic series on Fibrous Proteins in the Advances in Protein Chemistry serial. Fibrous proteins act as molecular scaffolds in cells providing the supporting structures of our skeletons, bones, tendons, cartilage, and skin. They define the mechanical properties of our internal hollow organs such as the intestines, heart, and blood vessels. This volume covers such topics as Beta-Structures in Fibrous Proteins; B-Silks: Enhancing and Controlling Aggregation; Beta-Rolls, Beta-Helices and Other Beta-Solenoid Proteins; Natural Triple B-Stranded Fibrous Folds; Structure, Function and Amyloidogenesis of Fungal Prions: Filament Polymorphism and Prion Variants; X-Ray Fiber and powder Diffraction of PRP Prion Peptides; From...
|

|
Alzheimer's Disease: Cellular and Molecular Aspects of Amyloid beta (Subcellular Biochemistry)
by Robin Harris (Editor), Falk Fahrenholz (Editor)
Preface: To understand Alzheimer?s disease (AD) is one of the major thrusts of present-day clinical research, strongly supported by more fundamental cellular, biochemical, immunological and structural studies. It is these latter that receive attention within this book. This compilation of 20 chapters indicates the diversity of work currently in progress and summarizes the current state of knowledge. Experienced authors who are scientifically active in their fields of study have been selected as contributors to this book, in an attempt to present a reasonably complete survey of the field. Inevitably, some exciting topics for one reason or another have not been included, for which we can only apologize. Standardization of terminology is often a problem in science, not least...
|
|
|
Nerve link: Alzheimer's suspect shows up in glaucoma.(This Week)(amyloid beta-protein): An article from: Science News
by N. Seppa (Author)
This digital document is an article from Science News, published by Thomson Gale on August 11, 2007. The length of the article is 483 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Nerve link: Alzheimer's suspect shows up in glaucoma.(This Week)(amyloid beta-protein) Author: N. Seppa Publication: Science News (Magazine/Journal) Date: August 11, 2007 Publisher: Thomson Gale Volume: 172 Issue: 6 Page: 84(2)
Distributed by Thomson...
|

|
Amyloid Proteins: The Beta Sheet Conformation and Disease
by Jean D. Sipe (Editor)
A first-stop reference on proteins associated with amyloidosis. This book is the first to present a systematic overview of all known fibril-forming proteins, including their biochemical characteristics and pathophysiology. It considers the clinically recognized amyloid proteins that are known to be associated with the amyloid protein folding disorders, dealing with their common structural and thermodynamic features that lead to amyloid fibril formation and disease. Emphasis is on the thermodynamics of protein folding, the structure and physiologic effects of common oligomeric and subfibrillar intermediates and the influence of the extracellular matrix and cellular trafficking and metabolism on the genesis and catabolism of beta pleated sheet proteins. The chapters on...
|
|
|
PET scans show [beta]-Amyloid, promise early Alzheimer's Dx. (Very Preliminary Data).: An article from: Family Practice News
by Miriam E. Tucker (Author)
This digital document is an article from Family Practice News, published by International Medical News Group on September 15, 2002. The length of the article is 468 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: PET scans show [beta]-Amyloid, promise early Alzheimer's Dx. (Very Preliminary Data). Author: Miriam E. Tucker Publication: Family Practice News (Magazine/Journal) Date: September 15, 2002 Publisher: International Medical News Group Volume: 32 Issue: 18 Page: 2(1)
Distributed by Thomson...
|
|
|
Beta amyloid: the peptide that kills from both the outside and inside to produce Alzheimer's disease. (Collegiate Communications--Undergraduate).(Brief ... of the North Dakota Academy of Science
by Jason Spah (Author), Katherine Splichal (Author), Kali Wilson (Author), Garl K. Rieke (Author)
This digital document is an article from Proceedings of the North Dakota Academy of Science, published by North Dakota Academy of Science on April 1, 2000. The length of the article is 897 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Beta amyloid: the peptide that kills from both the outside and inside to produce Alzheimer's disease. (Collegiate Communications--Undergraduate).(Brief Article) Author: Jason Spah Publication: Proceedings of the North Dakota Academy of Science (Refereed) Date: April 1, 2000 Publisher: North Dakota Academy of Science Page:...
|
|
|
Brain sabotage: Alzheimer's protein may spawn miniseizures.(This Week)(Amyloid beta-protein): An article from: Science News
by N. Seppa (Author)
This digital document is an article from Science News, published by Thomson Gale on September 15, 2007. The length of the article is 536 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Brain sabotage: Alzheimer's protein may spawn miniseizures.(This Week)(Amyloid beta-protein) Author: N. Seppa Publication: Science News (Magazine/Journal) Date: September 15, 2007 Publisher: Thomson Gale Volume: 172 Issue: 11 Page: 165(2)
Distributed by Thomson...
|
|
|
Genetic variant tied to amyloid-[beta] generation in Alzheimer's.(Geriatric Psychiatry)(Clinical report): An article from: Clinical Psychiatry News
by Jeff Evans (Author)
This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on April 1, 2007. The length of the article is 763 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Genetic variant tied to amyloid-[beta] generation in Alzheimer's.(Geriatric Psychiatry)(Clinical report) Author: Jeff Evans Publication: Clinical Psychiatry News (Magazine/Journal) Date: April 1, 2007 Publisher: Thomson Gale Volume: 35 Issue: 4 Page: 25(1)
Article Type: Clinical report
Distributed by Thomson...
|
|